Triple therapy after surgery for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in people with colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases) and who have already had surgery to remove as much cancer as possible. The goal is to see if this treatment can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove visible cancer from the lining of your abdomen (called cytoreductive surgery).
- Your cancer has spread to other parts of the body, but those spots are not expected to cause problems in the short term.
- You have already tried standard chemotherapy drugs (like oxaliplatin, irinotecan, or fluorouracil) and they no longer work or you couldn't tolerate them.
- Your cancer type is called microsatellite stable (MSS), which is a lab test result.
- You are at least 18 years old and your doctor estimates you will live more than 6 months.
- You are generally active and able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This trial compares two combination treatments for people with advanced colorectal cancer that has stopped responding to standard therapies. You would receive either trifluridine/tipiracil plus fruquintinib or trifluridine/tipiracil plus bevacizumab, to see which combination works better.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.